Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.56 |
| ▸ | RAB9A | P51151 | 6/20 | 0.56 |
| ▸ | HPGD | P15428 | 5/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.55 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 5/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | MMP13 | P45452 | 5/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | MMP2 | P08253 | 4/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4404148 | 0.89 | KDM4E (0.56) | KDM4EALDH1A1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL22620607 | 0.86 | KDM4E (0.53) | KDM4EALDH1A1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL22620608 | 0.86 | KDM4E (0.53) | KDM4EALDH1A1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL1883225 | 0.86 | ALOX15 (0.58) | KDM4EALDH1A1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL30193757 | 0.86 | ALOX15 (0.58) | KDM4EALDH1A1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL6739125 | 0.85 | KDM4E (0.58) | KDM4EALDH1A1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL25748437 | 0.85 | KDM4E (0.55) | KDM4EALDH1A1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL8959852 | 0.84 | KDM4E (0.51) | KDM4EALDH1A1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL22620609 | 0.84 | KDM4E (0.51) | KDM4EALDH1A1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL7954222 | 0.83 | ALOX15 (0.57) | KDM4EALDH1A1RAB9AHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8343981-B2 | Heterocyclyl-substituted dihydroquinazolines and their use as antiviral agents | AICURIS GMBH & CO. KG (DE) | 2013-01-01 | — | — | US | disclosed |
| US-8343981-B2 | Heterocyclyl-substituted dihydroquinazolines and their use as antiviral agents | AICURIS GMBH & CO. KG (DE) | 2013-01-01 | — | — | US | disclosed |
| US-8343981-B2 | Heterocyclyl-substituted dihydroquinazolines and their use as antiviral agents | AICURIS GMBH & CO. KG (DE) | 2013-01-01 | — | — | US | disclosed |
| US-20070185121-A1 | Heterocyclyl-substituted dihydroquinazolines and their use as antiviral agents | BAYER HEALTHCARE AG (DE) | 2007-08-09 | — | — | US | disclosed |
| US-20070185121-A1 | Heterocyclyl-substituted dihydroquinazolines and their use as antiviral agents | BAYER HEALTHCARE AG (DE) | 2007-08-09 | — | — | US | disclosed |
| US-20070185121-A1 | Heterocyclyl-substituted dihydroquinazolines and their use as antiviral agents | BAYER HEALTHCARE AG (DE) | 2007-08-09 | — | — | US | disclosed |
| US-6271251-B1 | CARDIOVASCULAR DISORDERS | SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) | 2001-08-07 | — | — | US | disclosed |
| US-5977100-A | Substituted guanidine derivatives, process for production thereof, and pharmaceutical uses thereof | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1999-11-02 | — | — | US | disclosed |
| US-5834454-A | TREATMENT OF ANGINA, ISCHEMIA, ARRHYTHMIA | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1998-11-10 | — | — | US | disclosed |
| EP-0787728-A1 | Substituted guanidine derivatives, process for production thereof, and pharmaceutical uses thereof | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1997-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185121-A1 | Heterocyclyl-substituted dihydroquinazolines and their use as antiviral agents | TYMP, RPL35, EIF2AK2 | KDM4E 2609/4885ALDH1A1 1660/4885RAB9A 1942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.